BC-1_Control

SRS8908002 SAMN19080781 GSM5287456 BC-1_Control_2 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BC-1 treatment No treatment for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908003 SAMN19080780 GSM5287457 BC-1_Wt_peptide_1 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BC-1 treatment Wild type peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908005 SAMN19080778 GSM5287459 BC-1_Mutant_peptide_1 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BC-1 treatment Mutant peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908006 SAMN19080777 GSM5287460 BC-1_Mutant_peptide_2 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BC-1 treatment Mutant peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908008 SAMN19080775 GSM5287462 BCBL-1_Control_2 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BCBL-1 treatment No treatment for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908010 SAMN19080773 GSM5287464 BCBL-1_Wt_peptide_2 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BCBL-1 treatment Wild type peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908011 SAMN19080784 GSM5287465 BCBL-1_Mutant_peptide_1 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BCBL-1 treatment Mutant peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908001 SAMN19080782 GSM5287455 BC-1_Control_1 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BC-1 treatment No treatment for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908004 SAMN19080779 GSM5287458 BC-1_Wt_peptide_2 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BC-1 treatment Wild type peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908007 SAMN19080776 GSM5287461 BCBL-1_Control_1 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BCBL-1 treatment No treatment for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908009 SAMN19080774 GSM5287463 BCBL-1_Wt_peptide_1 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BCBL-1 treatment Wild type peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour SRS8908012 SAMN19080783 GSM5287466 BCBL-1_Mutant_peptide_2 9606 Homo sapiens bioproject 728449 PRJNA728449 source_name human primary effusion lymphoma cell line BCBL-1 treatment Mutant peptide (24uM) for 90 minutes labeling treatment 4-Thiouridine (s4U; 300 uM) for 1 hour